Definitive Contract 75N93022C00017

This is a $299,959 SBIR Phase I contract awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to HDT Bio Corp, a biopharmaceutical company that develops drugs and vaccines for cancer, infectious diseases, and other unmet medical needs. The contract is for research, development, testing, and manufacturing services related to HDT Bio Corp's RNA technologies, adjuvants, antibodies, nanoparticles, and other platforms to create new medical...

This firm-fixed-price SBIR Phase I contract was awarded by the Department of Health and Human Services' National Institute of Allergy and Infectious Diseases to HDT Bio Corp, a for-profit biopharmaceutical company. The $599,629 contract funds the "Rational Development of a Combination Nanoparticle Adjuvant for Influenza", which involves research and development of novel adjuvants and other medical countermeasures. HDT Bio Corp has previously served as a prime contractor on other HHS...

<p>The federal contract award HHSN272201401008P was granted to Hycult Biotech Inc. by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the Department of Health and Human Services. The contract is for the delivery of antibodies, valued at $3,346.75 on a firm fixed price basis. The contract was awarded on September 3, 2014 with an ultimate completion date of October 3, 2014. The contract does not have a set-aside designation.</p>

This is a $18,576,013.05 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to the nonprofit research institute Access To Advanced Health Institute (AAHI), also known as Aahi, Idri, and Infectious Disease Research Institute. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant (AMR) infections, and emerging infectious...

The Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $16,345.50 purchase order to Biointron Biological USA Inc. for antibody expression services. As a firm fixed price contract, Biointron will provide the requested antibody expression services to NIH/NIAID at Metuchen, New Jersey from September 19, 2023 through December 29, 2023. No subcontractors or set aside designations were indicated. NIAID conducts and...

The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded Integrated Research Associates, LLC a $1.5 million firm fixed price definitive contract to advance the development of potent broad spectrum enterovirus A71 and D68 antibodies. Under this three year contract ending in June 2025, Integrated Research Associates will conduct advanced development of lead enterovirus A71 and D68 therapeutic candidates to address these viruses which can cause hand, foot...

The National Institute of Allergy and Infectious Diseases (NIAID), an agency within the U.S. Department of Health and Human Services, awarded a $18,500 firm-fixed-price purchase order to A&amp;G Pharmaceutical, Inc. (doing business as Precision Antibody) for laboratory testing, fusion, and cloning services. The contract has an ultimate completion date of November 30, 2024 and does not have a set-aside designation. This award is part of a larger $100 million Blanket Purchase Agreement (BPA)...

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price definitive contract to Integrated Research Associates, LLC, a woman-owned small business, for the Advancement of Potent Broad Spectrum Enterovirus A71 and D68 Antibodies. The contract, valued at $293,536.00, was awarded on August 14, 2020, with a completion date of August 13, 2021. The place of performance is San Rafael, California. There...

The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a $627,627.92 definitive contract to Nature's Toolbox Inc., doing business as Biotechnology, a subsidiary of Nature's Toolbox, Inc., for research and development of a novel, rapidly deployable RNA vaccine production platform under AOI #21 Vaccines on Demand. The firm fixed price contract will be performed in Mexico over a period of approximately two years, from April 2023 through...

This is a $599,999 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Parabon NanoLabs, Inc., a small business. The objective of the contract is to develop a DNA-based HIV vaccine that will stimulate production of broadly neutralizing antibodies against the HIV-1 envelope protein trimer antigen. This is a Phase I Small Business Innovation Research (SBIR) contract under the...